A Phase 1, Randomized, Placebo-Controlled, Multiple-Dose, Double-Blind Study to Evaluate and Compare the Pharmacokinetics and Safety of Rimegepant in Healthy Adult Japanese and Caucasian Individuals [0.03%]
一项针对成年日本受试者和白人受试者的瑞美吉泮药代动力学和安全性评价的I期、随机双盲、安慰剂对照及多剂量递增试验
Rajinder Bhardwaj,Chay Ngee Lim,Yinhua Li et al.
Rajinder Bhardwaj et al.
This Phase 1, randomized, placebo-controlled, double-blind study assessed the pharmacokinetic profile of rimegepant (25, 75, or 150 mg once daily for 14 days) in healthy Japanese and Caucasian adults. Exposures were modestly increased in Ja...
Comparison of Efficacy and Safety Profiles Between Omadacycline and Moxifloxacin in Elderly Patients with Community-Acquired Pneumonia: A Randomized, Controlled Trial [0.03%]
奥马环素与莫西沙星治疗社区获得性肺炎老年患者的疗效和安全性对比：一项随机对照试验
Muming Yu,Xiaorong Wang,Sitong Wu et al.
Muming Yu et al.
Omadacycline is a novel aminomethylcycline antibiotic that shows non-inferior efficacy to moxifloxacin in adults with community-acquired pneumonia (CAP), but lacking clinical evidence in elderly patients with CAP. This randomized, controlle...
A pharmacokinetics study to evaluate drug-drug interactions between fipaxalparant and concomitant medications in healthy participants [0.03%]
评价fipexide与帕兰联合用药在健康受试者中的药代动力学及药物相互作用研究
Yang Song,Krischan Hudson,Zhan Ye et al.
Yang Song et al.
Fipaxalparant, a small molecule and negative allosteric modulator of lysophosphatidic acid receptor 1, is being evaluated in phase 2 clinical trials of idiopathic pulmonary fibrosis (IPF) and diffuse cutaneous systemic sclerosis. This phase...
Bioequivalence Study of Two Olopatadine Hydrochloride Tablets in Chinese Healthy Subjects Under Fasting and Fed Conditions [0.03%]
奥洛他定 hydrochloride片在空腹及餐后条件下与参比制剂生物等效性研究-健康受试者中的一项随机、开放、两周期交叉试验
Yuyan Lei,Fang Pei,Qingqi Wu et al.
Yuyan Lei et al.
Olopatadine hydrochloride, a second-generation selective histamine H1 receptor antagonist, is an effective anti-allergic agent. This study evaluated the pharmacokinetics and bioequivalence of two olopatadine hydrochloride tablet formulation...
Comparative Bioequivalence and Safety Evaluation of Ibuprofen/Phenylephrine Hydrochloride Fixed-Dose Combination Tablets in Healthy Chinese Volunteers [0.03%]
对乙酰氨基酚/盐酸伪麻黄碱固定剂量复方 tablets在健康受试者中的生物等效性和安全性评价
Menghan Ye,Rui Zhang,Jing Wan et al.
Menghan Ye et al.
This single-center, randomized, open-label bioequivalence program compared two fixed-dose combination (FDC) tablets containing ibuprofen (200 mg) and phenylephrine hydrochloride (10 mg) from different manufacturers in healthy Chinese adults...
Integrating Pharmacogenomic Insights in GLP-1 Receptor Agonist Therapy: Direct GLP1R and ARRB1 Variants and Indirect CYP2D6 Influences in Personalized Obesity Management [0.03%]
GLP-1受体激动剂治疗中的药理基因组学见解整合：GLP1R和ARRB1变异体及CYP2D6的个性化肥胖管理的间接影响
Navodi Sandamini Jayathilaka,Arunodya Vishwanthi Weththasinghe,Nila Ganamurali et al.
Navodi Sandamini Jayathilaka et al.
Glucagon-like peptide-1 (GLP-1) receptor agonists have become frontline agents in obesity treatment due to their efficacy. However, there is considerable inter-individual variability in treatment response. Although these agents are primaril...
Amalia M Issa,Michael Fossler,Vijay V Upreti
Amalia M Issa
Clinical assessment of mocravimod as a victim of drug-drug interactions via CYP3A4 metabolism and transporters [0.03%]
莫考韦莫德临床评估：通过CYP3A4代谢和转运蛋白的药物相互作用受害者效应分析
Dymphy R Huntjens,Stephan Oehen,Elisabeth Kueenburg
Dymphy R Huntjens
Mocravimod, a novel immunomodulator targeting sphingosine-1-phosphate receptor (S1PR), is being developed as a maintenance treatment for patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Preclini...
Correction to "Preclinical and Phase 1 Assessment of Antisense Oligonucleotide Bepirovirsenin Hepatitis B Virus-Transgenic Mice and Healthy Human Volunteers: Support for Clinical Dose Selection and Evaluation of Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses" [0.03%]
“乙肝病毒转基因小鼠和健康志愿者的反义寡核苷酸倍比妥韦森药物的前期及一期评估：单次和多次给药的安全性、耐受性和药代动力学的临床剂量选择支持”一文的勘误
Published Erratum
Clinical pharmacology in drug development. 2025 Oct 27. DOI:10.1002/cpdd.1620 2025